The global large molecule bioanalytical testing services market size is expected to reach USD 3.70 billion by 2030, registering a CAGR of 9.63% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increased use of bioanalytical testing in clinical trials of biomarkers, large molecules, and other substances is the main driver of the industry. The rising incidence of chronic diseases and the rising demand for clinical trials in developing nations are the factors driving the market growth. For instance, according to the WHO, around 10 million people died from cancer in 2020. As per the estimates of cancer, 30.2 million people are likely to have cancer by 2040. Other factors that are anticipated to drive the segment growth include a rise in biologics, high demand for advanced technologies, and the need for personalized orphan drugs & medicines.
It is also projected that factors like technological advancement, globalization of clinical trials, and the rising need for CROs to perform clinical trials will accelerate industry expansion. Large pharmaceutical and bioanalytical firms, however, encountered difficulties as a result of the COVID-19 pandemic, which hampered clinical studies and treatments. Along with the workload of the COVID-19 project, which involves starting clinical trials, preclinical testing, doing bioanalysis, and interacting with regulatory bodies, other difficulties include the loss of workers at sites. The non-Covid initiatives were delayed, and there were lengthy 4-6 month wait times as a result of the resources being used to support the bioanalytical, preclinical, and clinical testing for the Covid trials. They must also resolve assays that are related to Covid and those that are not.
Request a free sample copy or view the report summary: Large Molecule Bioanalytical Testing Services Market Report
The clinical phase segment dominated the market in 2024 with the largest revenue share of 66.6%. The growing prevalence of chronic diseases and increasing demand for clinical trials in developing countries are factors expected to drive segment growth.
The global market is segmented into pharmacokinetics, Antidrug Antibodies (ADA), and others. The ADA segment accounted for the largest revenue share of the global market in 2024.
The bioavailability segment held the largest revenue share in 2024. The segment growth can be attributed to the high demand for these services in generic drug manufacturing.
Oncology accounted for a majority of revenue share in the global market in 2024. The segment is also anticipated to register the fastest CAGR during the forecast period.
The SMEs segment dominated the global market in 2024. The segment is also anticipated to grow at the fastest CAGR over the forecast timeline, retaining its market dominance.
North America large molecule bioanalytical testing services market dominated globally in 2024 with a revenue share of more than 48.94%.
Grand View Research has segmented the global large molecule bioanalytical testing services market on the basis of phase, test, type, therapeutic area, end use, and region:
Large Molecule Bioanalytical Testing Services Phase Outlook (Revenue, USD Million, 2018 - 2030)
Preclinical
With Antibody
Without Antibody (ELISA Based Assay)
Clinical
Large Molecule Bioanalytical Testing Services Type Outlook (Revenue, USD Million, 2018 - 2030)
Pharmacokinetics
ADA
Others
Large Molecule Bioanalytical Testing Services Test Outlook (Revenue, USD Million, 2018 - 2030)
ADME
PD
Bioavailability
Bioequivalence
Other Tests
Large Molecule Bioanalytical Testing Services Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
Oncology
Infectious Diseases
Cardiology
Neurology
Others
Large Molecule Bioanalytical Testing Services End Use Outlook (Revenue, USD Million, 2018 - 2030)
SMEs
CROs & CMOs
Sponsor Organizations
Others
Large Firms
CROs & CMOs
Sponsor Organizations
Others
Large Molecule Bioanalytical Testing Services Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
U.K.
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Thailand
South Korea
Australia
Latin America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Large Molecule Bioanalytical Testing Services Market
Laboratory Corporation of America Holdings
IQVIA
Syneos Health
SGS SA
WuXi AppTec
Intertek Group plc
Pace Analytical Services LLC
ICON Plc
Charles River Laboratories
Thermo Fisher Scientific
"The quality of research they have done for us has been excellent..."